

Zydus Cadila's EBIDTA up by 22% in Q3 on a sequential basis

Ahmedabad, February 7, 2019

For the third quarter ended December 31, 2018, Zydus Cadila reported Earnings before Interest, Depreciation and Tax (EBIDTA) of Rs. 840 crores, up 22% on a q-o-q basis. The total income from operations was up 21% q-o-q to Rs. 3578 crores and net profit was up 22% q-o-q to Rs. 511 crores.

The company's formulations business in the US posted sales of Rs. 1934 crores, up 46% on a q-o-q basis. During the quarter, the company launched 15 new products in the US and filed 9 additional ANDAs with the USFDA. The Company received 23 new product approvals (incl. 7 tentative approvals) from the USFDA during the quarter.
